Knight Therapeutics Inc KHTRF

Primary Symbol: T.GUD

Healthcare

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc > Increase by country 2020 to 2021

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Jan 16, 2023 3:42pm

106 Views

Post# 35226379

RE:Increase by country 2020 to 2021

Exactly Wofats - medicines are needed regardless of a market downturn or regardless of who's in power, etc.

It's about making the right strategic moves ... what to offer, price points, marketing, communications with physicians, etc.

I say LATAM is USA 1950 (or so) ... you want to be there ... and in other parts of the developing world. You want to offer a fully functioning system to a Big Pharma one day. IMO. Years down the road.

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments